Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Clinical trial NCT06569420 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06569420
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-31
- Primary completion
- 2025-07-31
- Enrollment
- 275
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.